Epstein-Barr virus-associated gastric cancer (EBVaGC) has long been regarded as the most immunologically favorable form of a ...

After enzalutamide, median scan-based progression-free survival was 9.1 months; Celcuity expects Phase 2 to start in the ...

Celcuity has an average rating of buy and mean price target of $154.69, according to analysts polled by FactSet.

In vitro PIK3CA silencing restored anoikis sensitivity and reduced aggressive behaviors in engineered anoikis-resistant ...

Next-generation CDK 4, CDK 2 and degrader strategies aim to overcome CDK4/6 resistance and reduce toxicity in HR+/HER2− ...

Phase III Krascendo 1 results demonstrated divarasibs superiority over current standard of care, first-generation KRAS G12C inhibitors, in previously treated advanced G12C-mutated non-small cell ...

A wave of new FDA approvals is giving breast cancer patients across multiple subtypes — from triple‑negative to HR+/HER2‑ disease — more options and more hope this year.

Celcuity Inc. announced that REVTORPYK? (gedatolisib) was now commercially available in the United States for eligible?HR+?), human epide ...

Dr. Jason Mouabbi introduces the discussion on managing PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer in clinical practice, with a focus on ...

ASCOLT's translational study found no survival benefit from aspirin in either prespecified subgroup: PIK3CA mutations or COX-2 overexpression. Pooling it with SAKK 41/13 and ALASCCA gave a 39% ...

MRC Human Genetics Unit, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, United Kingdom Edinburgh Cancer Research, CRUK Scotland Centre, Institute of Genetics and Cancer, The ...

Triplet gedatolisib/fulvestrant/palbociclib achieved the primary endpoint, significantly improving PFS versus alpelisib/fulvestrant in PIK3CA-mutant HR+/HER2− ...